Danaher Corporation
DHRDanaher Corporation (DHR) is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and consumer products and services. Founded in 1984, the company operates through various segments, including life sciences, diagnostics, and environmental & applied solutions, serving customers in health, environmental, and industrial markets worldwide. Danaher is known for its focus on continuous improvement and leveraging science and technology to solve complex problems.
Dividend History
Investors can expect a dividend payout of $0.32 per share, scheduled to be distributed in 24 days on January 30, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 30, 2026 | $0.32 | 2025-12-26 | 2025-12-26 |
| October 31, 2025 | $0.32 | 2025-09-26 | 2025-09-26 |
| July 25, 2025 | $0.32 | 2025-06-27 | 2025-06-27 |
| April 25, 2025 | $0.32 | 2025-03-28 | 2025-03-28 |
| January 31, 2025 | $0.27 | 2024-12-27 | 2024-12-27 |
Dividends Summary
- Danaher Corporation has issued 89 dividend payments over the past 22 years
- The most recent dividend was paid 67 days ago, on October 31, 2025
- The highest dividend payed out to investors during this period was $0.32 per share
- The average dividend paid during this period was $0.12 per share.
Company News
Brady Corporation held its annual shareholders meeting, unanimously electing a new Board of Directors and declaring a dividend of $0.245 per share, payable on January 30, 2026.
The article highlights top dividend stocks for 2026, focusing on companies positioned to benefit from anticipated interest rate cuts, AI advancements, and strategic market opportunities across sectors like pharmaceuticals, utilities, and consumer goods.
Questex's Fierce Biotech and Fierce Pharma announced the 2025 Life Sciences Innovation Awards, recognizing groundbreaking companies across various technological domains in healthcare and biotechnology.
Danaher reported strong Q3 earnings with core revenue growth of 3% and an adjusted operating profit margin of 27.9%, exceeding expectations. The company's performance was driven by strong bioprocessing business and better-than-anticipated respiratory revenue at Cepheid.
The article discusses the latest research reports on Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals, and Oil-Dri. It highlights the key strengths and challenges faced by these companies.
